Skip to content

ESC 2024: elevated blood pressure and hypertension

International ESC Current

2024 ESC Guidelines for the management of elevated blood pressure and hypertension

McEvoy JW, et al. Eur Heart J. 2024;45:3912–4018
DOI 10.1093/eurheartj/ehae178 · Summary checked against the source: 2026-11

Read or download the original

At a glance

  1. New three-way split: non-elevated BP (<120/70), elevated BP (120–139/70–89) and hypertension (≥140/90). [p. 3937]
  2. Treat by risk in the elevated band. Increased risk means established CVD, moderate–severe CKD, hypertension-mediated organ damage (HMOD), diabetes, familial hypercholesterolaemia, SCORE2/SCORE2-OP ≥10%, or 5–<10% plus risk modifiers. [p. 3963, 3990]
  3. Hypertension (≥140/90): start drugs promptly, whatever the risk. [p. 3991]
  4. Target systolic 120–129 (diastolic 70–79) for most adults, if tolerated. When that isn't possible, use "as low as reasonably achievable" (ALARA). [p. 3966]
  5. Start with a low-dose two-drug single pill: ACEi/ARB + CCB or diuretic. Step up to three drugs, then add spironolactone. [p. 3960]
  6. Keep treating lifelong, even after 85, if tolerated. [p. 3991]
  7. Renal denervation is not first-line. It's an option (IIb) only for resistant hypertension at an experienced centre. [p. 3981, 3991]

Classification and out-of-office thresholds

Adapted from ESC 2024 Table 5 and Figure 6 [p. 3933, 3937]

Office Home Daytime ABPM 24-h ABPM Night ABPM
Non-elevated <120/70 <120/70 <120/70 <115/65 <110/60
Elevated 120/70 to <140/90 120/70 to <135/85 120/70 to <135/85 115/65 to <130/80 110/60 to <120/70
Hypertension ≥140/90 ≥135/85 ≥135/85 ≥130/80 ≥120/70

Diagnosing hypertension [p. 3990]

flowchart TD
    A["Screening for hypertension by office BP"] --> NE["Non-elevated<br/><120/70"]
    A --> EL["Elevated<br/>120–139 / 70–89"]
    A --> H1["Hypertension<br/>140–159 / 90–99"]
    A --> H2["Hypertension<br/>160–179 / 100–109"]
    A --> H3["Hypertension<br/>≥180/110"]
    NE --> AGE{"Age ≥40?"}
    AGE -- No --> S3["Opportunistic screening<br/>at least every 3 years (IIa)"]
    AGE -- Yes --> S1["Opportunistic screening<br/>at least every year (IIa)"]
    EL --> RISK{"High CVD-risk condition, or<br/>SCORE2/SCORE2-OP ≥10%, or<br/>SCORE2 5–<10% + risk modifiers?"}
    RISK -- No --> S1
    RISK -- Yes --> C1["Confirm BP, preferably with<br/>home or ambulatory BP (I)"]
    H1 --> C1
    H2 --> C2["Confirm BP promptly, preferably with<br/>home or ambulatory BP (I)"]
    H3 --> EM["Evaluate for hypertensive emergency (I)"]
Adapted from ESC 2024 Figure 10 [p. 3944]

If home or ambulatory BP isn't feasible, confirm with repeated office readings on more than one visit. Confirm BP of 160–179/100–109 within about a month. [p. 3990]

Class I: measurement and work-up

  • Use a validated, calibrated device and a standard technique. Measure opportunistically in every adult and tell them the result.
  • Measure BP in both arms at the first visit. If they differ by >10 mmHg systolic, use the higher arm from then on.
  • Feel the pulse to check for atrial fibrillation.
  • Every patient with hypertension needs serum creatinine, eGFR, urine ACR and a 12-lead ECG. Repeat creatinine, eGFR and ACR at least yearly if CKD is moderate to severe.
  • Echocardiography if the ECG is abnormal or there are cardiac symptoms. Fundoscopy if BP >180/110, or the patient has diabetes.
  • Screen anyone diagnosed before age 40 for secondary hypertension. In obese young adults, start with sleep apnoea.

Class III

  • Routine genetic testing in hypertension.

Lifestyle [p. 3990–3991]

Class I

  • Sodium about 2 g/day (about 5 g of salt, or a teaspoon).
  • 150 min/week of moderate aerobic exercise (or 75 min vigorous), plus resistance training 2–3 times a week.
  • BMI 20–25. Waist <94 cm in men, <80 cm in women.
  • Mediterranean or DASH diet.
  • Alcohol below about 100 g/week; avoiding alcohol is best.
  • Free sugars below 10% of energy. Discourage sugar-sweetened drinks from childhood.
  • Stop smoking.

When to start drugs

Adapted from ESC 2024 Table 14 [p. 3963]

Non-elevated (<120/70) Elevated (120/70 to 139/89): lower risk Elevated: sufficiently high risk Hypertension (≥140/90)
Who SBP 120–129 (any risk), or SBP 130–139 with 10-year CVD risk <10% and no high-risk condition or risk modifier SBP 130–139 and one of: a high-risk condition (established CVD, diabetes, CKD, FH or HMOD), 10-year risk ≥10%, or risk 5–<10% plus risk modifiers or abnormal risk-tool tests Everyone: all are treated as high enough risk to benefit from drugs
Treatment Lifestyle for prevention; screen BP and CVD risk opportunistically Lifestyle measures; monitor BP and CVD risk yearly Lifestyle, then drugs after a 3-month delay if confirmed BP is still ≥130/80 Lifestyle and drugs straight away
Target Keep BP <120/70 Aim for 120–129 / 70–79 Aim for 120–129 / 70–79 Aim for 120–129 / 70–79

Class IIa: deferring drugs until BP ≥140/90

Start drugs only from ≥140/90 when there's pre-treatment symptomatic orthostatic hypotension, age ≥85, clinically significant moderate-to-severe frailty, or limited life expectancy (<3 years). [IIa, B · p. 3963]

Drug treatment

flowchart TD
    S["Low-dose double combination*<br/>ACEi or ARB / CCB / diuretic (I)"] --> C1{"Controlled after 1–3 months?<br/>(1-month review preferred)"}
    C1 -- Yes --> F["Follow up at least yearly"]
    C1 -- No --> T["Low-dose triple combination<br/>ACEi or ARB / CCB / diuretic (I)"]
    T --> C2{"Controlled after 1–3 months?"}
    C2 -- Yes --> F
    C2 -- No --> M["Maximally tolerated triple combination<br/>ACEi or ARB / CCB / diuretic (I)"]
    M --> C3{"Controlled after 1–3 months?"}
    C3 -- Yes --> F
    C3 -- No --> R["Apparent resistant hypertension<br/>refer to hypertension clinic (IIa)<br/>test for adherence (IIa)<br/>add spironolactone (IIa)"]
    X["*Initial monotherapy preferred: elevated BP band,<br/>moderate–severe frailty, symptomatic<br/>orthostatic hypotension, age ≥85"] -.-> S
    B["At any step: add a beta-blocker for a compelling<br/>indication: angina, post-MI, systolic HF,<br/>heart-rate control (I)"] -.-> T
Adapted from ESC 2024 Figure 18 [p. 3960]

Class I

  • First-line: ACE inhibitors, ARBs, dihydropyridine CCBs and diuretics (thiazides and thiazide-like: chlorthalidone, indapamide).
  • Beta-blockers go with another class only when there's a compelling indication.
  • Initial combination for most with confirmed BP ≥140/90. Preferred pair: RAS blocker + DHP CCB or diuretic, in a single pill.
  • If two drugs fail, move to three: RAS blocker + DHP CCB + thiazide or thiazide-like, preferably one pill.
  • Take the pills at whatever time of day suits the patient best.

Class III

  • ACE inhibitor + ARB together. [III, A]

Targets [p. 3966]

Class I, LOE A

  • Systolic 120–129 for most adults, if tolerated.
  • If that isn't tolerated: systolic as low as reasonably achievable (ALARA).

Class IIa

  • Age ≥85 or symptomatic orthostatic hypotension: a more lenient target (for example <140). [IIa, C]

Class IIb

  • Moderate–severe frailty or life expectancy under 3 years: lenient target (for example <140/90). [IIb, C]
  • Systolic on target but diastolic ≥80: stepping up treatment to reach diastolic 70–79 may be considered. [IIb, C]

Special groups [p. 3991–3992]

Class I

  • Elevated BP with diabetes: after up to 3 months of lifestyle change, start drugs if BP is still ≥130/80.
  • Target systolic 120–129 if tolerated.
  • Prediabetes or obesity: drugs at ≥140/90, or at 130–139/80–89 if 10-year risk is ≥10% or a high-risk condition is present, after 3 months of lifestyle change.

Class I

  • Moderate–severe CKD with BP ≥130/80: lifestyle plus drugs.
  • eGFR >30: target systolic 120–129 if tolerated. Individualise targets for lower eGFR or a kidney transplant.
  • SGLT2 inhibitor if eGFR >20.

Class I

  • Post-MI: beta-blocker + RAS blocker.
  • Angina: beta-blocker and/or CCB.
  • HFrEF/HFmrEF: ACEi (ARB if intolerant) or ARNI, beta-blocker, MRA, SGLT2 inhibitor.
  • HFpEF: SGLT2 inhibitor.

Class I

  • Stroke prevention: RAS blocker + CCB or thiazide-like diuretic.
  • After TIA or stroke with BP ≥130/80: target systolic 120–129.
  • Ischaemic stroke or TIA: start BP-lowering drugs before discharge. [I, B · p. 3984]

Class IIa: acute phase [p. 3984–3985]

  • Thrombolysis or thrombectomy: keep BP <180/105 for the first 24 h. [IIa, B]
  • No reperfusion and BP ≥220/110: lower by about 15% in the first 24 h. [IIa, C]
  • ICH: lower straight away (within 6 h) to systolic 140–160. [IIa, A]

Class III

  • ICH with systolic ≥220: don't drop systolic by >70 mmHg within the first hour. [III, B]

Class I

  • Gestational or chronic hypertension: start drugs at confirmed office ≥140/90.
  • Target <140/90, but diastolic not below 80.
  • First-line: DHP CCB (preferably extended-release nifedipine), labetalol, methyldopa.
  • Low- to moderate-intensity exercise for all pregnant women who can.

Class III

  • RAS blockers in pregnancy.

Class I

  • Under 85 and not moderately or severely frail: treat as for younger adults.
  • Check for orthostatic hypotension before starting or stepping up drugs (sit or lie 5 min, then measure at 1 and/or 3 min standing).
  • Orthostatic hypotension with supine hypertension: switch the offending drug rather than just reducing treatment.

Resistant hypertension [p. 3981–3982]

Class IIa, LOE B

  • Add spironolactone when BP stays uncontrolled on first-line drugs.
  • Spironolactone ineffective or not tolerated: switch to eplerenone, or add a beta-blocker. Next options: centrally acting drug, alpha-blocker, hydralazine or potassium-sparing diuretic.

Class IIb, LOE B

  • Catheter-based renal denervation for uncontrolled resistant hypertension on three drugs. Only at a medium- to high-volume centre, after a multidisciplinary assessment and if the patient wants it.

Class III

  • Renal denervation as first-line treatment.
  • Renal denervation when eGFR <40 or there's a secondary cause.
  • Renal artery angioplasty without a haemodynamically significant stenosis.

Clinical pearls

  • ESC still defines hypertension at ≥140/90. The 120–139/70–89 band is called "elevated BP".
  • The on-treatment target is a range (120–129), not just a ceiling.
  • The SCORE2 high-risk cut-off is 10% (AHA's PREVENT cut-off is 7.5%).
  • In ICH, ESC aims for 140–160 (AHA aims for 130–<140).
  • Spironolactone for resistant hypertension is IIa in ESC but Class 1 in AHA.

Classes and levels of evidence

How ESC 2024 grades its recommendations. Adapted from ESC 2024 Tables 1 and 2 [p. 3918–3919]. Hover over any class or level cited on this page to see what it means.

Class Meaning Wording used
Class I Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective is recommended or is indicated
Class IIa Weight of evidence or opinion is in favour of usefulness or efficacy should be considered
Class IIb Usefulness or efficacy is less well established by evidence or opinion may be considered
Class III Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful is not recommended
Level Meaning
Level A Data from multiple randomised clinical trials or meta-analyses
Level B Data from a single randomised clinical trial or large non-randomised studies
Level C Consensus of expert opinion and/or small studies, retrospective studies, registries

Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.